Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …

Immunotherapy is revolutionizing the management of multiple solid tumors, and early data
have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 …

The development of immune-check inhibitors has resulted in a paradigm shift for immune
oncology therapeutics in the past few decades. Blocking antibodies against programmed …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of
cancer death in women worldwide. Despite the significant benefit of the use of conventional …

Highlights•The investigation of immunotherapeutic agents for breast cancer has shifted from
the metastatic to the early setting.•Different scenarios and designs exist for clinical trials …

Breast Cancer (BC) is the second most frequent cause of cancer death among women
worldwide and, although there have been significant advances in BC therapies, a significant …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

More than 70% of breast cancers contain lymphocytic infiltration in the stroma, and
preclinical studies suggest that immunoediting and partial control of cancer progression by …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …